USPTO Examiner BEANE RANDALL L - Art Unit 1654

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18778554PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFJuly 2024December 2024Allow510YesNo
18419845SMALL PEPTIDE COMPOSITIONS AND USES THEREOFJanuary 2024June 2025Allow1701YesNo
18464046PTH ProdrugsSeptember 2023September 2024Allow1210NoNo
18365328LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOFAugust 2023March 2024Allow811YesNo
18345226DELIVERY OF CARD PROTEIN AS THERAPY FOR OCCULAR INFLAMMATIONJune 2023May 2025Allow2300YesNo
18212244Treatment of Muscular DystrophiesJune 2023February 2024Allow800YesNo
18331904LINKED AND OTHER pH-TRIGGERED COMPOUNDSJune 2023January 2025Abandon1911NoNo
18330032GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAMEJune 2023May 2025Abandon2301NoNo
18099378CROSSLINKED PARTICLES, COMPOSITION COMPRISING THE CROSSLINKED PARTICLES, METHOD FOR THE MANUFACTURE THEREOF, AND METHOD OF TREATING AN INFECTIONJanuary 2023June 2024Abandon1711NoNo
18096941USE OF COLLAGEN COMPOSITIONS FOR INCREASING TELOMERE LENGTHJanuary 2023March 2025Abandon2601NoNo
18093509DISULFIDE BOND CONTAINING COMPOUNDS AND USES THEREOFJanuary 2023April 2024Abandon1510NoNo
18053693PTH ProdrugsNovember 2022July 2023Allow811YesNo
18047150METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONOctober 2022October 2024Abandon2411NoNo
17935096CONTROLLABLE SELF-ANNEALING MICROGEL PARTICLES FOR BIOMEDICAL APPLICATIONSSeptember 2022November 2023Abandon1301NoNo
17778823MODULATORS OF PROGRAMMED DEATH-LIGAND-1 AND/OR PROGRAMMED DEATH-LIGAND-2May 2022May 2024Allow2421NoNo
17724900SMALL PEPTIDE COMPOSITIONS AND USES THEREOFApril 2022October 2023Allow1800YesNo
17687755MATING FACTOR ALPHA PRO-PEPTIDE VARIANTSMarch 2022February 2024Allow2401YesNo
17680070BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAMEFebruary 2022January 2025Abandon3521YesNo
17586737PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOFJanuary 2022March 2024Allow2611NoNo
17552748Pharmaceutical composition with improved stabilityDecember 2021November 2024Abandon3521NoNo
17532484COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOFNovember 2021November 2023Abandon2301NoNo
17612993VARIANT CD58 DOMAINS AND USES THEREOFNovember 2021March 2024Allow2701YesNo
17455649GDF15 FUSION PROTEINS AND USES THEREOFNovember 2021April 2025Abandon4141NoYes
17525531VARIANT OF A BPIFB4 PROTEINNovember 2021September 2023Allow2301YesNo
17608487INTERFERON REGULATORY FACTOR 5 INHIBITORS AND USES THEREOFNovember 2021March 2025Allow4021YesNo
17516977NOVEL DRUG DELIVERY CONJUGATED MOIETY FOR ORAL ADMINISTRATION OF DRUG UNSUITABLE FOR ORAL ADMINISTRATION AND PREPARATION METHOD THEREOFNovember 2021January 2024Abandon2601NoNo
17504072ALPHA(V)BETA(6) INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOFOctober 2021February 2024Allow2811YesNo
17503356Multivalent Plant Immune Fusion Protein, Production Method Thereof and Its UseOctober 2021April 2023Allow1811NoNo
17488137PTH ProdrugsSeptember 2021November 2022Abandon1421NoNo
17479705THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOFSeptember 2021November 2023Abandon2611NoNo
17434538POLYPEPTIDE HAVING ANTIBACTERIAL ACTIVITY, COMPOSITION FOR PREVENTING OR TREATING SEPSIS COMPRISING SAME, AND ANTIBACTERIAL COMPOSITIONAugust 2021April 2025Allow4420YesNo
17432077PEPTIDE-FUNCTIONALIZED BIODEGRADABLE POLYMERS FOR EFFICIENT DELIVERY OF VARIOUS RNASAugust 2021June 2025Allow4611YesNo
17429153TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERSAugust 2021January 2025Abandon4101NoNo
17393529BIOINSPIRED HIGHLY THERMO-SUSTAINABLE PACKINGS WITH USES THEREOFAugust 2021February 2023Abandon1801NoNo
17389761STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEINJuly 2021May 2023Abandon2101NoNo
17423341PROTEINS AND FLUOROPHORE-CONTAINING COMPOUNDS SELECTIVE FOR NaV1.7July 2021September 2024Abandon3821NoNo
17374437GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USESJuly 2021April 2023Abandon2101NoNo
17363698SPLIT INTEINS WITH EXCEPTIONAL SPLICING ACTIVITYJune 2021January 2025Allow4221YesNo
17358035Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated DiseasesJune 2021May 2024Abandon3411NoNo
17358142FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOFJune 2021January 2024Allow3141NoNo
17349669USE OF COLLAGEN COMPOSITIONS FOR INCREASING TELOMERE LENGTHJune 2021January 2023Abandon1921YesNo
17332338COMPOSITIONS FOR INHIBITING KRAS SIGNALING AND METHODS OF MAKING AND USING SAMEMay 2021May 2024Allow3531YesNo
17326247METHODS AND COMPOSITIONS FOR PROTEIN SEQUENCINGMay 2021April 2024Allow3511YesNo
17291616COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, COMPRISING AEG-1 S298D AS ACTIVE INGREDIENTMay 2021March 2025Allow4720NoNo
17306623DESIGNED, ENZYMATIC BIOCIDE FOR REMOVAL OF FOODBORNE MICROBIAL CONTAMINATIONMay 2021May 2023Abandon2501NoNo
17246307METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONApril 2021July 2022Allow1521YesNo
17240351FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAMEApril 2021July 2023Abandon2611NoNo
17287390PHARMACEUTICAL COMPOSITION COMPRISING TEICOPLANINApril 2021September 2024Abandon4001NoNo
17285811PYRROLOBENZODIAZEPINE CONJUGATESApril 2021September 2023Abandon2931NoNo
17224505TARGETED NON-INVASIVE IMAGING PROBES OF EGFR EXPRESSING CELLSApril 2021February 2023Allow2200YesNo
17282831HYPOGLYCEMIC PHARMACEUTICAL COMPOSITIONApril 2021May 2024Allow3811YesNo
17250969PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ULCER OR FISTULA IN INTESTINAL TRACTApril 2021June 2024Abandon3911NoNo
17281870ENGINEERED ACTIVE SINGLE-POLYPEPTIDE CHAIN INSULIN ANALOGSMarch 2021April 2024Allow3721YesNo
17280738NOVEL HYDROGEL CONJUGATESMarch 2021June 2025Abandon5021YesNo
17214530CYCLIC PEPTIDES TARGETING ALPHA-4-BETA-7 INTEGRINMarch 2021February 2023Abandon2301NoNo
17279772CD40L ANTAGONIST AND USES THEREOFMarch 2021April 2024Abandon3601YesNo
17279961COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTIONMarch 2021November 2024Allow4321YesNo
17279174GLP1-FC FUSION PROTEIN AND CONJUGATE THEREOFMarch 2021February 2025Abandon4721YesNo
17204627DELIVERY OF CARD PROTEIN AS THERAPY FOR OCCULAR INFLAMMATIONMarch 2021March 2023Allow2411YesNo
17185788EXPRESSION AND PURIFICATION OF CAS ENZYMESFebruary 2021November 2023Allow3211YesNo
17172533Method for accelerated healing of burn woundsFebruary 2021March 2024Abandon3720NoYes
17152239COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING SAMEJanuary 2021July 2023Abandon2911NoNo
17150426EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAMEJanuary 2021April 2024Allow3931NoNo
17144158CONTROLLABLE SELF-ANNEALING MICROGEL PARTICLES FOR BIOMEDICAL APPLICATIONSJanuary 2021June 2022Allow1700YesNo
17142276CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUSJanuary 2021January 2022Abandon1221NoNo
17137188PD-L 1-BINDING POLYPEPTIDE AND USE THEREOFDecember 2020November 2024Allow4711YesNo
17134185METHOD OF PRODUCING IMIDAZOLE DIPEPTIDESDecember 2020November 2024Abandon4631YesNo
17254391SUCCINIC ACID AND DERIVATIVES FOR THE TREATMENT OF HAEMOTOLOGICAL DISORDERSDecember 2020May 2024Abandon4011YesNo
17056545Translocation into Eukaryotic CellsNovember 2020February 2024Abandon3901NoNo
17055809MATRIX METALLOPROTEINASE-1 ANTISENSE OLIGONUCLEOTIDESNovember 2020March 2025Allow5211YesNo
17091500ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOFNovember 2020March 2025Allow5221NoNo
17084082XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAMEOctober 2020April 2023Abandon3011NoNo
17078978Bi-Specific Fusion ProteinsOctober 2020January 2023Allow2711YesNo
17048988A METHOD FOR PRODUCTION OF HIGH PURITY ICATIBANTOctober 2020August 2022Abandon2221NoNo
17045058FACTOR B AND C2 PROTEIN POINT MUTANTS, A METHOD FOR ENHANCING THE ACTIVITY OF ANTI-CANCER ANTIBODIES, THE PHARMACEUTICAL COMPOSITION AND THE USE OF MUTANTSOctober 2020March 2022Allow1820YesNo
17036396BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAMESeptember 2020April 2022Abandon1801NoNo
17028662Peptides Having Anti-Inflammatory PropertiesSeptember 2020October 2024Abandon4841NoNo
16982638CYCLIC TETRAPEPTIDE ANALOGSSeptember 2020March 2023Allow2901YesNo
16993702ZINC ACTIVATED THYMULIN AND METHODS OF PREPARATION AND ADMINISTRATIONAugust 2020January 2024Abandon4131YesNo
16991803Process for the Preparation of Insulin-Zinc ComplexesAugust 2020June 2024Abandon4631NoNo
16988302PTH PRODRUGSAugust 2020November 2023Abandon4021NoNo
16988386PTH PRODRUGSAugust 2020December 2023Abandon4021NoNo
16932113Method of Treating Parkinson's DiseaseJuly 2020October 2023Abandon3911NoNo
16927590MODULAR DIMERIZATION THERMOSWITCHES AND RELATED MONOMERS, DIMERS, CONSTRUCTS, DIMERIC COMPLEXES, VECTORS, CELLS, SURFACES, DEVICES COMPOSITIONS, METHODS AND SYSTEMSJuly 2020October 2023Allow4021YesNo
16901101INHIBITION-RESISTANT POLYMERASESJune 2020March 2025Allow5721YesYes
16898378THERAPEUTIC COMPOSITION FOR USE IN THE TREATMENT OF COVID-19 AND OTHER CYTOKINE STORM ASSOCIATED DISORDERSJune 2020October 2023Allow4051YesYes
16770299Methods For Treatment of Neuropathic PainJune 2020April 2025Abandon5931NoYes
16770358Treatment of Muscular DystrophiesJune 2020March 2023Allow3411YesNo
16768281METHODS FOR REDUCING RISK OF ONSET OF ACUTE GRAFT VERSUS HOST DISEASE AFTER HEMATOPOEITIC CELL TRANSPLANTATIONMay 2020August 2023Allow3921NoNo
16879534EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUEMay 2020May 2024Abandon4831YesNo
16872826METHODS OF INCORPORATING AN AMINO ACID COMPRISING A BCN GROUP INTO A POLYPEPTIDE USING AN ORTHOGONAL CODON ENCODING IT AND AN ORTHOGONAL PYLRS SYNTHASEMay 2020February 2023Allow3321YesNo
16762391GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOFMay 2020June 2024Abandon4931NoYes
16842408Drug Delivery Enhancement AgentsApril 2020June 2022Abandon2721NoNo
16651921LONG ACTING PROTEIN COMPLEX HAVING AN ENHANCED EFFICIENCYMarch 2020February 2024Abandon4761YesNo
16651813POLYION COMPLEX POLYPEPTIDE HYDROGELS AND USES THEREOFMarch 2020October 2024Allow5451YesNo
16650719CROSSLINKED PARTICLES, COMPOSITION COMPRISING THE CROSSLINKED PARTICLES, METHOD FOR THE MANUFACTURE THEREOF, AND METHOD OF TREATING AN INFECTIONMarch 2020May 2023Abandon3841NoNo
16642233PHARMACEUTICAL COMPOSITION FOR TREATING KELOID AND USES THEREOFFebruary 2020May 2024Abandon5141YesNo
16777125GLUCAGON-LIKE PEPTIDE-2 COMPOSITIONS AND METHODS OF MAKING AND USING SAMEJanuary 2020September 2023Abandon4331YesNo
16634099MALARIA VACCINEJanuary 2020September 2024Abandon5641YesNo
16633610SUPERACTIVE MUTANT THYMIDINE KINASE FOR USE IN CANCER THERAPYJanuary 2020July 2022Abandon3011NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BEANE, RANDALL L.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
36.5%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
33
Allowed After Appeal Filing
5
(15.2%)
Not Allowed After Appeal Filing
28
(84.8%)
Filing Benefit Percentile
15.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BEANE, RANDALL L - Prosecution Strategy Guide

Executive Summary

Examiner BEANE, RANDALL L works in Art Unit 1654 and has examined 295 patent applications in our dataset. With an allowance rate of 36.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner BEANE, RANDALL L's allowance rate of 36.9% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BEANE, RANDALL L receive 2.06 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BEANE, RANDALL L is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +53.7% benefit to allowance rate for applications examined by BEANE, RANDALL L. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 10.4% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.6% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 46% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.7% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.